THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence

Description

The purpose of this study is to pilot and refine an online behavioral intervention based on Positive Affect Training (PAT) that aims to increase positive emotional attitudes and decrease negative emotional attitudes toward endocrine therapy (ET, i.e., anti-hormonal medication) and to increase positive affect and decrease negative affect more generally, among post-treatment breast cancer survivors who are prescribed ET to prevent recurrence of breast cancer.

Conditions

Breast Cancer, DCIS

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to pilot and refine an online behavioral intervention based on Positive Affect Training (PAT) that aims to increase positive emotional attitudes and decrease negative emotional attitudes toward endocrine therapy (ET, i.e., anti-hormonal medication) and to increase positive affect and decrease negative affect more generally, among post-treatment breast cancer survivors who are prescribed ET to prevent recurrence of breast cancer.

Pilot Study of Positive Affect Training for Endocrine Therapy Medication Adherence

THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Boulder

University of Colorado Boulder, Boulder, Colorado, United States, 80309

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * hormone receptor-positive breast cancer stages 0-3
  • * have finished primary treatment (chemotherapy/radiation/surgery)
  • * are prescribed endocrine therapy (ET) currently or within the last two years
  • * score above specified cut off (range, 0-10) on any of three questions:
  • 1. How upset are you by having to take anti-hormonal therapy
  • 2. How bothered are you by the side effects?
  • 3. How difficult is it for you to take your anti-hormonal medication every day?
  • * have internet access to complete online assessments and intervention components or agree to use and return a study wifi-activated iPad.
  • * metastatic disease
  • * Individuals who are unable to interact with the intervention as needed. This includes those who are extremely visually impaired to the degree that they cannot see the screen and interact as required and individuals who cannot read and/or write in English. This is due to the nature of the intervention itself. If a participant is unable to interact with THRIVE as required, they are unlikely to benefit from the intervention or offer insightful feedback that can be used in refining the program.

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Joanna Arch,

Joanna Arch, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Boulder

Study Record Dates

2024-12-12